Skip to content

Cumulative EFfects of Intravenous Treatments in Cystic Fibrosis

Cumulative EFfects of Intravenous Treatments in Cystic Fibrosis: a cross-sectional observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN44660887
Enrollment
80
Registered
2010-01-12
Start date
2009-11-01
Completion date
Unknown
Last updated
2018-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cystic fibrosis Nutritional, Metabolic, Endocrine Cystic fibrosis

Interventions

As an observational study, there is only one arm. After consent, each patient has a Chromium 51 EDTA based glomerular filtration rate (GFR test). A hearing assessment is performed, which consists of a

Sponsors

The University of Nottingham (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Cystic fibrosis (defined as a positive sweat test, or genetic PLUS clinical features, or positive screening test, or CF in sibling) 2. Participant or participants legally acceptable representative must be able to give informed consent 3. Aged 5 years and over, both males and females

Exclusion criteria

Exclusion criteria: 1. Intravenous antibiotics in the last 2 weeks 2. Participation in another research project which excludes the patient from this study 3. Poor patient prognosis, and the clinician feels that this or other difficult family circumstances would make taking part in the research inappropriate 4. A postive pregnancy test

Design outcomes

Primary

MeasureTime frame
1. The prevalence of chronic kidney disease (GFR less than 80 ml/min/1.73 square metres) 2. The prevalence of hearing impairment 3. The association between cumulative lifetime exposure to intravenous aminoglycosides and GFR will be explored with multiple regression, after adjustment for potential confounders Both primary and secondary outcomes will be assessed when all patients have completed the study protocol.

Secondary

MeasureTime frame
1. Cystatin C in the blood 2. Agreement between cystatin C based formula for GFR and measured GFR (using Cr51EDTA) 3. Genetic analysis methods will depend upon the numbers of participants who have poor kidney function or hearing impairment. Thus after preliminary data regarding these are available, a plan for genetic analyses will be proposed. Both primary and secondary outcomes will be assessed when all patients have completed the study protocol.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 15, 2026